Evidence map›Paper›PMID 30344180›Full record

ArticleBMJ open2018

ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial.

Louise China, Simon S Skene, Kate Bennett, Zainib Shabir, Roseanna Hamilton, Scott Bevan, Torsten Chandler, Alexander A Maini, Natalia Becares, Derek Gilroy and 2 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Disease Modulating Agents in Cirrhosis.Clinics in liver disease · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Hypoalbuminemia as Surrogate and Culprit of Infections.International journal of molecular sciences · 2021
    Review
  13. Article
  14. Review
  15. Immune Regulatory Mediators in Plasma from Patients With Acute Decompensation Are Associated With 3-Month Mortality.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Louise ChinaDivision of Medicine, University College London, London, UK.ORCID 0000-0001-5870-2310
Simon S SkeneSchool of Biosciences and Medicine, University of Surrey, Guildford, UK.ORCID 0000-0002-7828-3122
Kate BennettComprehensive Clinical Trials Unit, UCL, London, UK.
Zainib ShabirComprehensive Clinical Trials Unit, UCL, London, UK.
Roseanna HamiltonComprehensive Clinical Trials Unit, UCL, London, UK.
Scott BevanComprehensive Clinical Trials Unit, UCL, London, UK.
Torsten ChandlerComprehensive Clinical Trials Unit, UCL, London, UK.
Alexander A MainiDivision of Medicine, University College London, London, UK.
Natalia BecaresDivision of Medicine, University College London, London, UK.
Derek GilroyDivision of Medicine, University College London, London, UK.
Ewan H ForrestDepartment of Gastroenterology, Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, UK.
Alastair O'BrienDivision of Medicine, University College London, London, UK.
MRC Clinical Trials Unit at UCL · GBUniversity College London · GBNHS Greater Glasgow and Clyde · GBUniversity of Surrey · GB

Funding

Department of HealthWellcome Trust
6 · The paper itself

Abstract

introductionCirculating prostaglandin E METHODS AND ANALYSIS: Albumin To prevenT Infection in chronic liveR failurE stage 2 is a multicentre, open-label, interventional RCT. Patients with decompensated cirrhosis admitted to the hospital with a serum albumin of <30 g/L are eligible, subject to exclusion criteria. Patients randomised to intravenous HAS will have this administered, according to serum albumin levels, for up to 14 days or discharge. The infusion protocol aims to increase serum albumin to near-normal levels.The composite primary endpoint is: new infection, renal dysfunction or mortality within the trial treatment period. Secondary endpoints include mortality at up to 6 months, incidence of other organ failures, cost-effectiveness and quality of life outcomes and time to liver transplant. The trial will recruit 866 patients at more than 30 sites across the UK. ETHICSANDDISSEMINATION: Research ethics approval was given by the London-Brent research ethics committee (ref: 15/LO/0104). The clinical trials authorisation was issued by the medicines and healthcare products regulatory agency (ref: 20363/0350/001-0001). The trial is registered with the European Medicines Agency (EudraCT 2014-002300-24) and has been adopted by the National Institute for Health Research (ISRCTN 14174793). This manuscript refers to version 6.0 of the protocol. Results will be disseminated through peer-reviewed journals and international conferences. Recruitment of the first participant occurred on 25 January 2016.

Indexed as

Bacterial InfectionsClinical Trials, Phase III as TopicCross InfectionEnd Stage Liver DiseaseHumansImmunocompromised HostInfusions, IntravenousLiver CirrhosisMulticenter Studies as TopicRandomized Controlled Trials as TopicRenal InsufficiencySerum AlbuminSerum Albumin, HumanSerum AlbuminSerum Albumin, Humanadult gastroenterology

Identifiers

PMID30344180
PMCPMC6196858
OpenAlexW2911416835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.